Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis
Table 1
Inclusion criteria for the systematic literature review according to PICOS methodology.
PICOS
Inclusion criteria
Population
Adults (≥18 years) with acute symptomatic PAD
Intervention/comparators
RIV+ASA±CLO ASA CLO CLO+ASA VKA monotherapy VKA±(ASA or CLO)
Outcomes of interest
Efficacy including the following: ALI, major amputation, MI, IS, CV death Hospitalization for a coronary or peripheral cause (either lower limb) of a thrombotic nature All-cause death Safety including the following: Bleeding (major, minor, requiring medical attention, GI, intracranial, and fatal) AEs (severe, treatment-emergent) Haemorrhagic stroke Thrombotic thrombocytopenic purpura
